Erectile dysfunction and hypogonadism among men with HIV

AIDS Patient Care and STDs

Volumn 21, Issue 1, 2007, Pages 9-19

  Crum Cianflone, Nancy F ^a,b   Bavaro, Mary ^b   Hale, Braden ^b   Amling, Christopher ^b   Truett, April ^b   Brandt, Carolyn ^a   Pope, Brandie ^a   Furtek, Kari ^a   Medina, Sheila ^a   Wallace, Mark R ^b  

^a Tri Service AIDS Clinical Consortium   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; BENZODIAZEPINE DERIVATIVE; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; HYPOCHOLESTEROLEMIC AGENT; NARCOTIC AGENT; NEVIRAPINE; PHOSPHODIESTERASE V INHIBITOR; PROTEINASE INHIBITOR; SILDENAFIL; STAVUDINE; TENOFOVIR; TESTOSTERONE; ZIDOVUDINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; ERECTILE DYSFUNCTION; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PENIS ERECTION; PREVALENCE; QUESTIONNAIRE; RISK FACTOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SMOKING; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL;

ADULT; AGE FACTORS; AGED; ANTI-HIV AGENTS; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; DEPRESSION; ETHNIC GROUPS; HIV INFECTIONS; HUMANS; HYPOGONADISM; IMPOTENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; SMOKING; STATISTICS; TESTOSTERONE;

EID: 33846828729     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0071     Document Type: Article

References (51)

1. Feldman HA, Goldstein I, Hatzichrisou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
2. Dobs AS, Dempsey MA, Ladenson PW, et al. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988;84:611-616.
3. Tindall B, Forde S, Goldstein D, et al. Sexual dysfunction in advanced HIV disease. AIDS Care 1994;6:105-107.
4. Cove J, Petrak J. Factors associated with sexual problems in HIV-positive gay men. Int J STD AIDS 2004;15:732-736.
5. Lallemand F, Salhi Y, Linard F, et al. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr 2002;30:187-190.
6. Lamba H, Goldmeier D, Mackie NE, et al. Antiretroviral therapy is associated with sexual dysfunction and with increased serum oestradiol levels in men. Int J STD AIDS 2004;15:234-237.
7. Ende AR, Lo Re V 3rd, DiNubile MJ, Mounzer K. Erectile dysfunction in an urban HIV-positive population. AIDS Patient Care STDs 2006; 20:75-78.
8. Martinez E, Collazos J, Mayo J, et al. Sexual dysfunction with protease inhibitors. Lancet 1999;353:810-811.
9. Colebunders R, Smets E, Verdonck K, et al. Sexual dysfunction with protease inhibitors. Lancet 1999;353:1802.
10. Colson AE, Keller MJ, Sax PE, et al. Male sexual dysfunction associated with antiretroviral therapy. J Acquir ImmuneDefic Syndr 2002;30:27-32.
11. Schrooten W, Colebunders R, Youle M, et al. Eurosupport Study Group. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 2001;15:1019-1023.
12. Sollima S, Osio M, Muscia F, et al. Protease inhibitors and erectile dysfunction. AIDS 2001;15:2331-2333.
13. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDs 2005;19:655-671.
14. Morgentaler A. A 66-year-old man with sexual dysfunction. JAMA 2004;291:2994-3003.
15. McCutchan A, Jacobson D, Robinson R, et al. Impact of hypogonadism on sexual function in HIV/AIDS [Abstract WS-B23-6]. Int Conf AIDS 1993;9:66.
16. Meyer-Bahlburg HF, Dolzeal C, Stern Y, et al. Sexual dysfunction in homosexual HIV+ men: Association with immune function, endocrine, neurologic and psychiatric factors [Abstract PO-B16-1689]. Int Conf AIDS 1993;9:417.
17. Cofrancesco J Jr, Whalen JJ 3rd, Dobs AS. Testosterone replacement treatment options for HIV-infected men. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:254-265.
18. Shabsigh R, Kaufman JM, Steidle C, et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-663.
19. Mikhail N, Does testosterone have a role in erectile function? Am J Med 2006;119:373-382.
20. Rietschel P, Corcoran C, Stanley T, et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000;31:1240-1244.
21. Fisher A, Desyatnik M, Baaj A. The prevalence of hypogonadism in HIV infected patients receiving HAART [Abstract no. TuPeB3180). Int Conf AIDS 2000;13.
22. Wagner G, Rabkin JG, Rabkin R. Illness stage, concurrent medications, and other correlates of low testosterone in men with HIV illness. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:204-207.
23. Mylonakis E, Koutkia P, Grinspoon S. Diagnosis and treatment of androgen deficiency in human immunodeficiency virus-infected men and women. Clin Infect Dis 2001;33:857-864.
24. Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab 1998;12:379-390.
25. Rosen RC, Seidman SN, Menza MA, et al. Quality of life, mood, and sexual function: A path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004;16:334-340.
26. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830.
27. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-1242.
28. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988;8:77-100.
29. Althof SE, Corty EW, Levine SB, et al. EDITS: Developing of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999;53:793-799.
30. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-544.
31. Cruess DG, Evans DI, Repetto MJ, et al. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003;54:307-316.
32. Cachay E, Mar-Tang M, Mathews WC. Screening for potentially transmitting sexual risk behaviors, urethral sexually transmitted infection, and sildenafil use among males entering care for HIV infection. AIDS Patient Care STDs 2004;18:349-354.
33. Kim AA, Kent CK, Dlausner JD. Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000-2001. AIDS 2002;16:1425-1428.
34. Swearingen SG, Klausner JD. Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection. Am J Med 2005;118:571-577.
35. Sanchez TH, Gallagher KM for the HITS-2002 Investigators. Factors associated with recent sildenafil (Viagra) use among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2006;42:95-100.
36. Sadeghi-Nejed H, Watson R, Irwin R, et al. Lecture 5: Erectile dysfunction in the HIV-positive male: A review of medical, legal and ethical considerations in the age of oral pharmacotherapy. Int J Impot Res 2000;12(Suppl 3):S49-53.
37. Kell P, Sadeghi-Nejad H, Price D. An ethical dilemma: Erectile dysfunction in the HIV-positive patient: To treat or not to treat. Int J STD AIDS 2002;13:355-357.
38. Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999;13:F101-F107.
39. Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50:99-107.
40. Berger D, Muurahainen N, Wittert H, et al. Hypogonadism and wasting in the era of HAART in HIV-infected patients [Abstract 32174]. Int Conf AIDS 1998;12:555.
41. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-5926.
42. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-598.
43. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;85:724-731.
44. Niskanen L, Laaksonen DE, Punnonen K, et al. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004;6:208-215.
45. Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: A prospective cohort study. J Clin Endocrinol Metab 2005;90:712-719.
46. Barbieri RL, Gochberg J, Ryan KJ. Nicotine, cotinine, and anabasine inhibit aromatase in human trophoblast in vitro. J Clin Invest 1986;77:1727-1733.
47. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996;17:518-532.
48. Tancredi A, Reginster JY, Schleich F, et al. Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol 2004;151:355-360.
49. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogondadal men. J Clin Endocrinol Metab 2000;85:2670-2677.
50. Rabkin JG, Rabkin R, Wagner GJ. Testosterone treatment of clinical hypogonadism in patients with HIV/AIDS. Intl J STD AIDS 1997;8:537-545.
51. Makhsida N, Shah J, Yan G, et al. Hypogonadism and metabolic syndrome: Implications for testosterone therapy. J Urol 2005;174:827-834.